Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.

Category Primary study
JournalAntimicrobial agents and chemotherapy
Year 2007
Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.
Epistemonikos ID: bc5c8c9a662b8cca5907ee68d4ba1ad2911a6513
First added on: Dec 06, 2021